Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice with Best Practices and Guidelines (Virtual)

Description

Here is the Meeting Flyer. 

The Maryland Dermatologic Society cordially invites you to attend a CME activity that aims to improve learners’ knowledge, confidence, and competence in effectively using immune checkpoint inhibitors to improve outcomes in patients with basal cell carcinoma and cutaneous squamous cell carcinoma.

Justine V. Cohen, D.O., is a medical oncologist at the Center for Cancer Therapeutic Innovation (Early Drug Development Program). She is a Senior Physician at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School specializing in immunotherapy and targeted therapy for melanoma and cutaneous cancers.

AMA PRA Category 1 Credit™, ABIM MOC, ANCC, AAPA, and ACPE- certified live webinar titled, “Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice With Best Practices and Guidelines.”

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Disclosures will be made known to learners before the activity. We invite you to share this event with your colleagues by forwarding this email.

For full accreditation information, click here.